|
1
|
Warnakulasuriya S: Global epidemiology of
oral and oropharyngeal cancer. Oral Oncol. 45:309–316. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Lambert R, Sauvaget C, de Camargo Cancela
M and Sankaranarayanan R: Epidemiology of cancer from the oral
cavity and oropharynx. Eur J Gastroenterol Hepatol. 23:633–641.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Weatherspoon DJ, Chattopadhyay A,
Boroumand S and Garcia I: Oral cavity and oropharyngeal cancer
incidence trends and disparities in the United States: 2000–2010.
Cancer Epidemiol. 39:497–504. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Ghantous Y, Yaffi V and Abu-Elnaaj I: Oral
cavity cancer: Epidemiology and early diagnosis. Refuat Hapeh
Vehashinayim. 32(55–63): 712015.(In Hebrew).
|
|
5
|
Ito Y: Oncogenic potential of the RUNX
gene family: ‘Overview’. Oncogene. 23:4198–4208. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Tonomoto Y, Tachibana M, Dhar DK, Onoda T,
Hata K, Ohnuma H, Tanaka T and Nagasue N: Differential expression
of RUNX genes in human esophageal squamous cell carcinoma:
Downregulation of RUNX3 worsens patient prognosis. Oncology.
73:346–356. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Ito K, Liu Q, Salto-Tellez M, Yano T, Tada
K, Ida H, Huang C, Shah N, Inoue M, Rajnakova A, et al: RUNX3, a
novel tumor suppressor, is frequently inactivated in gastric cancer
by protein mislocalization. Cancer Res. 65:7743–7750. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Soong R, Shah N, Peh BK, Chong PY, Ng SS,
Zeps N, Joseph D, Salto-Tellez M, Iacopetta B and Ito Y: The
expression of RUNX3 in colorectal cancer is associated with disease
stage and patient outcome. Br J Cancer. 100:676–679. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Yu GP, Ji Y, Chen GQ, Huang B, Shen K, Wu
S and Shen ZY: Application of RUNX3 gene promoter methylation in
the diagnosis of non-small cell lung cancer. Oncol Lett. 3:159–162.
2012.PubMed/NCBI
|
|
10
|
Lau QC, Raja E, Salto-Tellez M, Liu Q, Ito
K, Inoue M, Putti TC, Loh M, Ko TK, Huang C, et al: RUNX3 is
frequently inactivated by dual mechanisms of protein
mislocalization and promoter hypermethylation in breast cancer.
Cancer Res. 66:6512–6520. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Bai J, Yong HM, Chen FF, Song WB, Li C,
Liu H and Zheng JN: RUNX3 is a prognostic marker and potential
therapeutic target in human breast cancer. J Cancer Res Clin Oncol.
139:1813–1823. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Kim BR, Kang MH, Kim JL, Na YJ, Park SH,
Lee SI, Kang S, Joung SY, Lee SY, Lee DH, et al: RUNX3 inhibits the
metastasis and angiogenesis of colorectal cancer. Oncol Rep.
36:2601–2608. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Chen H, Wang Z, Wang S, Zhang Z and Shi S:
Effect and mechanism of RUNX3 gene on biological characteristics of
human esophageal squamous cell carcinoma (ESCC). Med Oncol.
32:3572015. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Mei PJ, Bai J, Liu H, Li C, Wu YP, Yu ZQ
and Zheng JN: RUNX3 expression is lost in glioma and its
restoration causes drastic suppression of tumor invasion and
migration. J Cancer Res Clin Oncol. 137:1823–1830. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Tsunematsu T, Kudo Y, Iizuka S, Ogawa I,
Fujita T, Kurihara H, Abiko Y and Takata T: RUNX3 has an oncogenic
role in head and neck cancer. PLoS One. 4:e58922009. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Kudo Y, Tsunematsu T and Takata T:
Oncogenic role of RUNX3 in head and neck cancer. J Cell Biochem.
112:387–393. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Tanji Y, Osaki M, Nagahama Y, Kodani I,
Ryoke K and Ito H: Runt-related transcription factor 3 expression
in human oral squamous cell carcinomas; implication for tumor
progression and prognosis. Oral Oncol. 43:88–94. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Gao F, Huang C, Lin M, Wang Z, Shen J,
Zhang H, Jiang L and Chen Q: Frequent inactivation of RUNX3 by
promoter hypermethylation and protein mislocalization in oral
squamous cell carcinomas. J Cancer Res Clin Oncol. 135:739–747.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Subramaniam MM, Chan JY, Soong R, Ito K,
Ito Y, Yeoh KG, Salto-Tellez M and Putti TC: RUNX3 inactivation by
frequent promoter hypermethylation and protein mislocalization
constitute an early event in breast cancer progression. Breast
Cancer Res Treat. 113:113–121. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Supic G, Kozomara R, Jovic N, Zeljic K and
Magic Z: Hypermethylation of RUNX3 but not WIF1 gene and its
association with stage and nodal status of tongue cancers. Oral
Dis. 17:794–800. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Shi M, Wang Z, Liu XY and Chen D:
Inactivation of RUNX3 predicts poor prognosis in esophageal
squamous cell carcinoma after Ivor-Lewis esophagectomy. Med Oncol.
31:3092014. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Cheng HC, Liu YP, Shan YS, Huang CY, Lin
FC, Lin LC, Lee L, Tsai CH, Hsiao M and Lu PJ: Loss of RUNX3
increases osteopontin expression and promotes cell migration in
gastric cancer. Carcinogenesis. 34:2452–2459. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Subramaniam MM, Chan JY, Yeoh KG, Quek T,
Ito K and Salto-Tellez M: Molecular pathology of RUNX3 in human
carcinogenesis. Biochim Biophys Acta. 1796:315–331. 2009.PubMed/NCBI
|
|
24
|
Romana PG: WITHDRAWN: Cell alterations and
molecular mechanisms in oral carcinogenesis. Int J Oral Maxillofac
Surg. Aug 4–2010.(Epub ahead of print). View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Chen F, Bai J, Li W, Mei P, Liu H, Li L,
Pan Z, Wu Y and Zheng J: RUNX3 suppresses migration, invasion and
angiogenesis of human renal cell carcinoma. PLoS One. 8:e562412013.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Krstic J and Santibanez JF: Transforming
growth factor-beta and matrix metalloproteinases: Functional
interactions in tumor stroma-infiltrating myeloid cells. Sci World
J. 2014:5217542014. View Article : Google Scholar
|
|
27
|
Martin MD and Matrisian LM: The other side
of MMPs: Protective roles in tumor progression. Cancer Metastasis
Rev. 26:717–724. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Peng Z, Wei D, Wang L, Tang H, Zhang J, Le
X, Jia Z, Li Q and Xie K: RUNX3 inhibits the expression of vascular
endothelial growth factor and reduces the angiogenesis, growth, and
metastasis of human gastric cancer. Clin Cancer Res. 12:6386–6394.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Cao EG, Wang E, Pal K, Dutta SK, Bar-Sagi
D and Mukhopadhyay D: VEGF exerts an angiogenesis-independent
function in cancer cells to promote their malignant progression.
Cancer Res. 72:3912–3918. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Lee JH, Pyon JK, Kim DW, Lee SH, Nam HS,
Kang SG, Kim CH, Lee YJ, Chun JS and Cho MK: Expression of RUNX3 in
skin cancers. Clin Exp Dermatol. 36:769–774. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Hiramatsu T, Osaki M, Ito Y, Tanji Y,
Tokuyasu N and Ito H: Expression of RUNX3 protein in human
esophageal mucosa and squamous cell carcinoma. Pathobiology.
72:316–324. 2005. View Article : Google Scholar : PubMed/NCBI
|
